Hinge Health stock clears major IPO level and catches Wall Street’s attention
HNGE rallies above $43.80 buy zone on strong technical setup
Hinge Health, a leader in AI-driven virtual physical therapy, has decisively cleared its first IPO buy point at $43.80. Shares rallied about 6 %, trading near $44 after an impressive 17 % pop over the IPO price on its NYSE debut.
Rapid revenue growth sets strong foundation
HNGE posted $123.8 million in Q1 revenue, up 50 % year-over-year, treating over 532,000 patients and partnering with more than 2,250 employers. The TrueMotion technology powering its platform has earned strong technical ratings, although annual net profits remain in progress.
Strong RS score fuels optimism, but breakout must hold
With a Relative Strength (RS) score of 86, Hinge ranks as a top IPO in medical technology. Analysts widely recommend 'buy' or 'strong buy,' with ambitious price targets ranging from $45 to $52. The key now is whether HNGE sustains the breakout with expanding trade volume.